Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Histone H3 is a nuclear protein and a component of the nucleosome core, a basic unit of chromatin, that is essential for organizing genomic DNA in eukaryotic nuclei.1 It is a globular protein that contains an unstructured N-terminal tail that extends outside of the nucleosome core and is subject to various post-translational modifications (PTMs), including methylation, phosphorylation, acetylation, and citrullination.1,2 Acetylation of histone H3 at lysine 18 (H3K18Ac) by histone acetyltransferases (HATs) is associated with active gene transcription, whereas deacetylation of H3K18Ac by histone deacetylases (HDACs), including SIRT7, induces transcriptional repression.3 Tumor H3K18Ac hypoacetylation is associated with poor prognosis and increased risk of tumor recurrence in patients with lung adenocarcinoma or kidney clear cell carcinoma.4 Cayman's Histone H3K18Ac Monoclonal Antibody (RM166) can be used for chromatin immunoprecipitation (ChIP), ELISA, immunocytochemistry (ICC), immunohistochemistry (IHC), multiplex-based assay, and Western blot (WB) applications.
WARNING This product is not for human or veterinary use.
1. Writing, erasing and reading histone lysine methylations. Exp. Mol. Med. 49(4), e324 (2017).
2. Histone posttranslational modifications: Potential role in diagnosis, prognosis, and therapeutics of cancer. Prognostic Epigenetics 15, 351-373 (2019).
3. SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature 487(7405), 114-118 (2012).
4. Global levels of histone modifications predict prognosis in different cancers. Am. J. Pathol. 174(5), 1619-1628 (2009).